MedTrace Logo

Observation in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Treated on Clinical Trial CAN-NCIC-LY9

NCT00400907 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 667

Last updated 2011-12-20

No results posted yet for this study

Summary

RATIONALE: Treatment for diffuse large B-cell non-Hodgkin's lymphoma may cause side effects and secondary cancers later in life. An observational study that evaluates patients after undergoing six courses of combination chemotherapy with or without rituximab and radiation therapy may help doctors predict a patient's response to this treatment and help plan the best treatment.

PURPOSE: This observational study is evaluating patients with diffuse large B-cell non-Hodgkin's lymphoma to see how well treatment on clinical trial CAN-NCIC-LY9 works.

Conditions

  • Long-term Effects Secondary to Cancer Therapy in Adults
  • Lymphoma

Interventions

OTHER

clinical observation

PROCEDURE

management of therapy complications

Sponsors & Collaborators

  • German High-Grade Non-Hodgkin's Lymphoma Study Group

    lead OTHER

Principal Investigators

  • Michael G.M. Pfreundschuh, MD · Universitaetsklinikum des Saarlandes

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00400907 on ClinicalTrials.gov